Category - Developments

Developments

AUM Biosciences going public through merger with Mountain Crest Acquisition

Closely-held AUM Biosciences, which is advancing a broad portfolio of precision oncology therapeutics, entered into a definitive business combination agreement with Mountain Crest Acquisition Corp. V (NASDAQ:MCAG). The...

October 21, 2022

Developments

Hepion Pharma food effect study with rencofilstat published

The peer-reviewed journal, Clinical Pharmacology in Drug Development, published the results of a clinical trial examining the effect of food on the oral bioavailability of Hepion Pharmaceuticals’ (NASDAQ:HEPA) lead drug...

October 21, 2022

Developments

IntelGenx receives new U.S. patent on VersaFilm technology

IntelGenx Corp. (TSX:IGX; OTCQB:IGXT) received U.S. Patent No. 11,471,406 from the United States Patent and Trademark Office, with claims for modulating drug absorption in oral film dosage form designed for sublingual...

October 20, 2022

Developments

Jazz Pharma in license for Zymeworks’ HER2 zanidatamab

Jazz Pharmaceuticals (NASDAQ:JAZZ) inked an exclusive licensing agreement to acquire development and commercialization rights to Zymeworks’ (NYSE:ZYME) zanidatamab across all indications in the United States, Europe...

October 19, 2022

Developments

Ondine presents effective photodisinfection treatment research against MRSA

Ondine Biomedical (LON:OBI) presented new research at the Infection Prevention Society Conference in Bournemouth, UK showing that its Steriwave photodisinfection technology is highly effective against clinical MRSA...

October 19, 2022

Developments

LENZ Therapeutics posts positive Phase 2 presbyopia treatment data

Closely-held LENZ Therapeutics reported positive topline results from its Phase 2 INSIGHT clinical trial of two investigational formulations of aceclidine to treat presbyopia, or farsightedness. Both LNZ100 (aceclidine)...

October 18, 2022

Developments

Comera reports favorable preclinical results of lead SQore excipient

Comera Life Sciences (NASDAQ:CMRA) reported favorable results from its recently completed SEQURUS-2 study. Together with the SEQURUS-1 study. the preclinical results showed that Comera’s caffeine-based SQore...

October 18, 2022

Developments

IntelGenx submits response to CRL from FDA for RIZAPORT VersaFilm

IntelGenx (TSX:IGX; OTCQB:IGXT) responded to the complete response letter (CRL) for its 505(b)(2) NDA for RIZAPORT VersaFilm received from the FDA in March 2020. “We have been encouraged by our interactions with...

October 18, 2022

Developments

TIAP and Evotec expand LAB150 BRIDGE partnership to Include Amgen

Toronto Innovation Acceleration Partners (TIAP) and Evotec (NASDAQ:EVO; FSE: EVT) have expanded LAB150, their translational BRIDGE partnership, to include Amgen (NASDAQ:AMGN) as a strategic partner. The expansion...

October 17, 2022

Developments

IntelGenx updates atai collaboration as first-in-human study launched of an oral film psychedelic drug candidate

IntelGenx (TSX:IGX; OTCQB:IGXT) updated its collaboration with strategic partner, atai Life Sciences (NASDAQ:ATAI), which has begun a first-in-human Phase 1 study for the development of novel formulations of...

October 13, 2022

Category - Developments

Subscribe